REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

Cantor Fitzgerald said the positive panel outcome materially improves the chances of accelerated approval for Replimune's RP1 therapy.

The FDA decision on RP1 is expected by Aug. 2.

REPL stock tracks its best day ever following the panel outcome.

The panel outcome was described as 'overwhelmingly positive' by the analyst.